Replies to post #114653 on Innovation Pharmaceuticals Inc (IPIX)

[Fletch]

Whoever is trying to scare you out of your shares.....just say NO.....I'm a holding and I will be rewarded,
Fletch

[TOB]

That's just nonsense.

News this year hasn't done a thing to the PPS. In fact, the PPS is down 40 percent YTD. Again, I'm not happy to do a RS, but hopefully the past few weeks has swayed Leo's strategy to form a partnership. -Rdunn88

The share price pulled back to near its previous level after a break-out from a range. It hasn't declined below that range. It is very typical to see rally legs pull back and test prior levels.

Share price and partnerships are entirely unrelated items. There is no pressure for CTIX to partner. They can do so when the deal is "spectacular" as the CEO has said.

You are also ignoring obvious factors.

1. The large share transfer that likely created selling pressure. Since then the share price has leveled off, and had a rally leg that broke above the recent range.

2. The amount down YTD was from an all-time rally high reached last December. That was actually the second year out of three that CTIX has an exuberant rally in December which later pulled back.

3.The pending up-listing to the NASDAQ is likely just weeks away, not months.

Leo said, he's hopeful the PPS would rise with news... This was before K and B news... If he doesn't want a RS and news doesn't drive the PPS higher, then the only alternative is to license out B... -Rdunn88

There has been no significant Kevetrin news yet. The trial is ongoing. The Brilacidin news of the Phase 3 go ahead is still in its early days. The market reacts in its own timing, and will play catch up as the Phase 3 trial progresses.

There are also several other trials in progress or soon to start. Summer is a notoriously slow season, the following months have historically been very good for CTIX. CTIX is has more news catalysts pending.

Going to be hard raising enough funds on a corrupt pink-sheet market. Also, if new investors aren't attractive to the stock, then the alternative could be bankruptcy or sell off the scraps like Polymedix did. Using the pink sheets as your line-of-credit is dangerous. -Rdunn88

That is detached from reality.

1. Cellceutix has an existing favourable financing deal with Aspire sufficient for the ongoing trials. The second such deal, larger that the first. CTIX doesn't need to raise money from the "market".

2. Talk of "bankruptcy or sell off the scraps like Polymedix did." is absurd. Cellceutix is better funded than ever before in its history. It has plenty of funding to draw from at favourable terms from Aspire. Lol at bankruptcy.

3. "Using the pink sheets as your line-of-credit is dangerous." Cellceutix has a favourable financing deal in place from Aspire Capital. The terms are superior to what is common in the emerging biotech space and sufficient for the ongoing clinical trials. There is no "line-of-credit" from the "pink sheets". Lol